Abstract: The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and/or cancerous diseases or conditions.

Abstract: The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. The programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, gastric motility, and volume and viscosity of gastric fluid. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm, e.g., that matches the human circadian rhythm of a condition's symptoms and/or of the individual being treated in the application of the therapy to optimize therapeutic outcome and minimize side effects.

Abstract: An object of the present invention is to provide a copolymer which is capable of forming a viscous aqueous solution having a desired viscosity in the presence of an electrolyte, in particular, a polyvalent electrolyte, a thickening agent comprising the copolymer, and a cosmetic preparation comprising the copolymer. The present invention relates to an acrylic acid ester (A)/compound (B) copolymer, comprising, as constitutional components, an acrylic acid ester (A) and a compound (B), wherein the acrylic acid ester (A) is represented by the general formula [1], and the compound (B) has, in each molecule, a polymerizable unsaturated group and any functional group selected from the group consisting of a carboxyl group, a sulfo group, and a phosphate group, and a weight ratio of the acrylic acid ester (A) and the compound (B), which is (A)/(B), is 9.0/91.0 to 28.5/71.

Abstract: Instantly dissolving buccal films comprising certain pH modifiers, film formers, film modifiers, and solubilizing agents are provided. Methods of providing the buccal film to enhance the dissolution and bioavailability of low solubility basic drugs, such as dapoxetine hydrochloride, in a subject are also provided.

Abstract: The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles.

Abstract: A stabilized composition for the controlled delivery of probiotics includes an aqueous solution of crystalloids and colloids comprised of water insoluble polymers with the ability to de-swell upon electrical charge. The composition further includes a plurality of oil droplets and a base solution. The composition further include a destabilizing solution comprising a solvent, nitrogen, a natural acid sufficient to produce a pH of about 3.0 to about 4.5, and a sufficient amount of a salt to contribute to an osmolality between about 190 mOsm/L and about 900 mOsm/L. The composition further includes a plurality of microencapsulated probiotic beads, wherein the plurality of microencapsulated probiotic beads comprises between about 0.01% to about 20% of the composition by weight.

Abstract: A liquid or semi-solid matrix or magma or paste which is non-newtonian, thixotropic and pseudoplastic and composed of one or more controlled release agent, and/or one or more clays such as bentonite and/or one or more fillers in a non aqueous vehicle, and optionally materials selected from disintegrants, humectants, surfactants and stabilizers. The composition and physicochemical properties makes it harder or prevents dose dumping of narcotic analgesics in the presence of alcohol and harder to abuse opiod agonists or narcotic analgesics and discourages drug abuse via crushing, milling or grinding the dosage form to powder or heating the dosage form to vapour and snorting or inhalation by the nasal route or dissolving to abuse via the parenteral route.

Abstract: Techniques regarding treating one or more microbe infections with combination therapy are provided. For example, one or more embodiments described herein can comprise a method, which can comprise enhancing an antimicrobial activity of an antibiotic by a combination therapy. The combination therapy can comprise the antibiotic and a polycarbonate polymer functionalized with a guanidinium functional group.

Abstract: Low dose pharmaceutical formulations may be prepared to deliver consistent low doses of a variety of pharmaceuticals with minimal additives. In particular, the low dose pharmaceutical formulations are solid unit dosage forms of low dose drug substances which may be prepared by a method that provides content uniformity across prepared solid unit dosage forms.

Abstract: The present disclosure provides improved film based pharmaceutical products containing uniformly distributed drug or active agent particles (e.g., to achieve improved/excellent dissolution control including enhancing dissolution and bioavailability and/or product uniformity). More particularly, the present disclosure provides improved systems/methods for fabricating film based pharmaceutical products by utilizing higher surface modified micronized drug or active agent powders and film forming precursors and drying methods that accomplish improved/efficient drying and provide improved/excellent content uniformity of active pharmaceutical agents in the fabricated film based pharmaceutical products. In exemplary embodiments, the present disclosure provides for an easier means of directly incorporating dry micronized poorly water-soluble drugs or active agent particles (e.g., fenofibrate (“FNB”)) into films.

Abstract: Anti-microbial compositions comprising (a) a quaternary ammonium compound and (b) a cationic biocide. Applicant has discovered a synergistic combination of the two components with the ration of cationic biocide to quaternary ammonium being less than 1:10 or with a single quaternary compound in a ratio of less than 1.6 to 1 provide a film forming coating that has residual anti-bacterial activity and improved durability with strong resistance to general wear between applications.

Abstract: A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains an adhesive base and an antioxidant containing a sulfur atom in its molecule.

Abstract: Disclosed are tissue graft compositions made of particles having different densities, methods of making these compositions, and methods of using these compositions for promoting tissue restoration in a patient.

Abstract: Foamable formulations of agriculturally active ingredients are provided, as well as methods for using them. The formulations allow improved delivery active ingredients by the ability to deliver high amounts of active ingredient with a low volume of formulation used.

Abstract: The present invention relates to a composition for the protection against solar radiation, consisting of an organic matrix, preferably a gelatin, and hydroxyapatite nanoparticles modified by the substitution of part of the phosphorus with titanium, and part of the calcium with iron.

Abstract: Inserts can be formed with elution characteristics to cause the inserts to elute an antimicrobial agent when subject to a fluid within a medical device. An insert can be formed with a desired geometry to allow the insert to be compression fit within a medical device to prevent the insert from moving or becoming dislodged once inserted into the medical device. The material may also be hygroscopic so that the insert swells when subject to a fluid thereby enhancing the compression fit of the device within the medical device. In some cases, the material can be reinforced using an internal structure. Inserts can be formed in many ways including by casting, thermoforming, or extrusion. In some cases, the inserts can be formed using a peel-away sleeve or material. The peel-away sleeves can be formed of a non-sticky material which facilitates removal of the inserts once the inserts have cured.

Abstract: Foamable formulations of agriculturally active ingredients are provided, as well as methods for using them. The formulations allow improved delivery active ingredients by the ability to deliver high amounts of active ingredient with a low volume of formulation used.

Abstract: Lipid microcapsules are described that can include at least one irritant active substance, more specifically a retinoid, in a soluble form. Also described, are pharmaceutical compositions comprising the same, and methods for the production thereof. A method of using the composition to treat dermatological pathologies is also described.

Abstract: The present invention provides a patch containing an adhesive layer maintaining a drug, which is formed on a support, wherein the aforementioned adhesive layer comprises a thermoplastic elastomer, a non-volatile hydrocarbon oil in an amount exceeding 50 parts by weight and not more than 800 parts by weight per 100 parts by weight of the elastomer, and rivastigmine or a salt thereof, and the aforementioned adhesive layer optionally further contains a tackifier at a content in the adhesive layer of not more than 10 wt %.

Abstract: Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1? in the wound.